RFP | November 13, 2014
District of Columbia's Amyotrophic Lateral Sclerosis (ALS) Association announces the availability of funding for implementation of the Phase II Clinical Development of Novel, High-Potential Treatments for People With ALS Grant. The purpose of this grant is to expedite the process of bringing new treatments forward for testing in people with ALS and to measure if that therapeutic agent is reaching its target. A letter of intent to bid is due 1/9/2015 . . .